Understanding how aging immune cells contribute to Alzheimer's disease
Metabolic Control of T Cell Senescence in Pathogenesis and Immunotherapy of Alzheimer's Disease
This study is looking at how aging immune cells called T cells might affect the buildup of harmful proteins in Alzheimer's disease, with the hope of finding new ways to help people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11080924 on NIH RePORTER |
What this research studies
This research investigates the role of aging immune cells, specifically T cells, in the development and progression of Alzheimer's disease (AD). It aims to uncover the mechanisms by which senescent T cells may influence the accumulation of harmful proteins associated with AD, such as amyloid beta and Tau. By studying these processes, the research seeks to identify potential new therapeutic strategies that could improve treatment options for patients with AD. The approach includes analyzing the metabolic activity and secretory profiles of these immune cells in both human samples and animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research include older adults who are at risk of developing Alzheimer's disease or those already diagnosed with the condition.
Not a fit: Patients with early-onset Alzheimer's disease or those with non-age-related forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that slow down or prevent the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in understanding the immune system's role in neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Peng, Guangyong — Washington University
- Study coordinator: Peng, Guangyong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.